Clinical & Translational Immunology

Papers
(The median citation count of Clinical & Translational Immunology is 4. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
Endothelial cells are not productively infected by SARS‐CoV‐294
Antibodies against type I interferon: detection and association with severe clinical outcome in COVID‐19 patients82
A scalable serology solution for profiling humoral immune responses to SARS‐CoV‐2 infection and vaccination81
CAR‐NK cells: the next wave of cellular therapy for cancer74
Allogeneic CD20‐targeted γδ T cells exhibit innate and adaptive antitumor activities in preclinical B‐cell lymphoma models59
Comprehensive analysis of SARS‐CoV‐2 antibody dynamics in New Zealand52
Patient‐derived organoids of bladder cancer recapitulate antigen expression profiles and serve as a personal evaluation model for CAR‐T cells in vitro48
Preclinical development of a molecular clamp‐stabilised subunit vaccine for severe acute respiratory syndrome coronavirus 246
Pattern of circulating SARS‐CoV‐2‐specific antibody‐secreting and memory B‐cell generation in patients with acute COVID‐1946
Dynamics of antibodies to SARS‐CoV‐2 in convalescent plasma donors45
Rheumatoid arthritis CD14+ monocytes display metabolic and inflammatory dysfunction, a phenotype that precedes clinical manifestation of disease43
Pathogenesis of autoimmune demyelination: from multiple sclerosis to neuromyelitis optica spectrum disorders and myelin oligodendrocyte glycoprotein antibody‐associated disease41
Kinetics of peripheral blood neutrophils in severe coronavirus disease 201939
Arrested development: suppression of NK cell function in the tumor microenvironment39
The up‐to‐date pathophysiology of Kawasaki disease38
Natural killer cells in inflammatory autoimmune diseases37
Decline in neutralising antibody responses, but sustained T‐cell immunity, in COVID‐19 patients at 7 months post‐infection37
The complex interplay between endoplasmic reticulum stress and the NLRP3 inflammasome: a potential therapeutic target for inflammatory disorders35
Type 1 conventional dendritic cells and interferons are required for spontaneous CD4+ and CD8+ T‐cell protective responses to breast cancer34
SARS‐CoV‐2‐specific humoral and cellular immunity persists through 9 months irrespective of COVID‐19 severity at hospitalisation34
RGD‐binding integrins and TGF‐β in SARS‐CoV‐2 infections – novel targets to treat COVID‐19 patients?34
Prophylactic antigen‐specific T‐cells targeting seven viral and fungal pathogens after allogeneic haemopoietic stem cell transplant31
Cardiovascular disease in SARS‐CoV‐2 infection31
Cerebrospinal fluid metabolomics: detection of neuroinflammation in human central nervous system disease31
TGF‐β‐secreting regulatory B cells: unsung players in immune regulation29
Molecular and cellular mechanisms of itch and pain in atopic dermatitis and implications for novel therapeutics29
Ligelizumab treatment for severe asthma: learnings from the clinical development programme28
Systematic evaluation of SARS‐CoV‐2 antigens enables a highly specific and sensitive multiplex serological COVID‐19 assay28
Off‐target effects of bacillus Calmette–Guérin vaccination on immune responses to SARS‐CoV‐2: implications for protection against severe COVID‐1927
High levels of soluble CD25 in COVID‐19 severity suggest a divergence between anti‐viral and pro‐inflammatory T‐cell responses26
Lysine methyltransferase G9a is an important modulator of trained immunity26
An acetate‐yielding diet imprints an immune and anti‐microbial programme against enteric infection26
Robust correlations across six SARS‐CoV‐2 serology assays detecting distinct antibody features26
Influenza, but not SARS‐CoV‐2, infection induces a rapid interferon response that wanes with age and diminished tissue‐resident memory CD8+ T cells26
Blunted sFasL signalling exacerbates TNF‐driven neutrophil necroptosis in critically ill COVID‐19 patients25
Circular RNA TRAPPC6B inhibits intracellular Mycobacterium tuberculosis growth while inducing autophagy in macrophages by targeting microRNA‐874‐3p25
Novel high‐affinity EGFRvIII‐specific chimeric antigen receptor T cells effectively eliminate human glioblastoma23
Autoantibodies against complement component C1q in systemic lupus erythematosus23
Humoral immunity against SARS‐CoV‐2 variants including omicron in solid organ transplant recipients after three doses of a COVID‐19 mRNA vaccine23
Improvement of Treg immune response after treatment with tocilizumab in giant cell arteritis22
Memory stem T cells modified with a redesigned CD30‐chimeric antigen receptor show an enhanced antitumor effect in Hodgkin lymphoma22
Inflammatory marker trajectories associated with frailty and ageing in a 20‐year longitudinal study22
Impact of SARS‐CoV‐2 infection on vaccine‐induced immune responses over time21
Optimising the IgG‐degrading enzyme treatment regimen for enhanced adeno‐associated virus transduction in the presence of neutralising antibodies19
Differential transcriptional and functional properties of regulatory T cells in HIV‐infected individuals on antiretroviral therapy and long‐term non‐progressors19
Heterogeneous magnitude of immunological memory to SARS‐CoV‐2 in recovered individuals19
Modelling the tumor immune microenvironment for precision immunotherapy19
Next‐generation Bruton's tyrosine kinase inhibitor BIIB091 selectively and potently inhibits B cell and Fc receptor signaling and downstream functions in B cells and myeloid cells18
Nalfurafine reduces neuroinflammation and drives remyelination in models of CNS demyelinating disease18
SLAMF8 expression predicts the efficacy of anti‐PD1 immunotherapy in gastrointestinal cancers18
Circulating CD8+ mucosal‐associated invariant T cells correlate with improved treatment responses and overall survival in anti‐PD‐1‐treated melanoma patients18
Landscape of T‐cell repertoires with public COVID‐19‐associated T‐cell receptors in pre‐pandemic risk cohorts18
Characteristics of T‐cell responses in COVID‐19 patients with prolonged SARS‐CoV‐2 positivity – a cohort study18
Sustained low‐dose interleukin‐2 therapy alleviates pathogenic humoral immunity via elevating the Tfr/Tfh ratio in lupus17
C‐reactive protein flare‐response predicts long‐term efficacy to first‐line anti‐PD‐1‐based combination therapy in metastatic renal cell carcinoma17
Increased GM‐CSF‐producing NCR ILC3s and neutrophils in the intestinal mucosa exacerbate inflammatory bowel disease17
Quantification and role of innate lymphoid cell subsets in Chronic Obstructive Pulmonary Disease17
Exploiting the CRISPR‐Cas9 gene‐editing system for human cancers and immunotherapy17
Whole‐blood cytokine secretion assay as a high‐throughput alternative for assessing the cell‐mediated immunity profile after two doses of an adjuvanted SARS‐CoV‐2 recombinant protein vaccine candidate17
SARS‐CoV‐2 triggers complement activation through interactions with heparan sulfate16
IgM and IgA augmented autoantibody signatures improve early‐stage detection of colorectal cancer prior to nodal and distant spread16
Inflammasome activation: from molecular mechanisms to autoinflammation16
Epigenetic programming underpins B‐cell dysfunction in peanut and multi‐food allergy16
TIGIT blockade enhances NK cell activity against autologous HIV‐1‐infected CD4+ T cells16
Inflammation neuroscience: neuro‐immune crosstalk and interfaces16
Human neutralising antibodies elicited by SARS‐CoV‐2 non‐D614G variants offer cross‐protection against the SARS‐CoV‐2 D614G variant16
Tumor‐associated neutrophils (TANs) in human carcinoma‐draining lymph nodes: a novel TAN compartment15
Antibodies to neutralising epitopes synergistically block the interaction of the receptor‐binding domain of SARS‐CoV‐2 to ACE 215
Proinsulin‐specific T‐cell responses correlate with estimated c‐peptide and predict partial remission duration in type 1 diabetes15
Adenoviral vector‐based platforms for developing effective vaccines to combat respiratory viral infections15
T‐cell response after first dose of BNT162b2 SARS‐CoV‐2 vaccine among healthcare workers with previous infection or cross‐reactive immunity15
IL‐17 drives salivary gland dysfunction via inhibiting TRPC1‐mediated calcium movement in Sjögren’s syndrome15
Tear antibodies to SARS‐CoV‐2: implications for transmission15
Mutated GM‐CSF‐based CAR‐T cells targeting CD116/CD131 complexes exhibit enhanced anti‐tumor effects against acute myeloid leukaemia15
Human regulatory T cells locally differentiate and are functionally heterogeneous within the inflamed arthritic joint15
Deficient DNASE1L3 facilitates neutrophil extracellular traps‐induced invasion via cyclic GMP‐AMP synthase and the non‐canonical NF‐κB pathway in diabetic hepatocellular carcinoma14
Regulation of the human NK cell compartment by pathogens and vaccines14
Adaptive immunity to human coronaviruses is widespread but low in magnitude14
Intratumoral injection of caerin 1.1 and 1.9 peptides increases the efficacy of vaccinated TC‐1 tumor‐bearing mice with PD‐1 blockade by modulating macrophage heterogeneity and the activation of CD814
Perivascular macrophages create an intravascular niche for CD8+ T cell localisation prior to the onset of fatal experimental cerebral malaria14
SARS‐CoV‐2 sculpts the immune system to induce sustained virus‐specific naïve‐like and memory B‐cell responses13
Understanding the tumor microenvironment in head and neck squamous cell carcinoma13
Parallel detection of SARS‐CoV‐2 epitopes reveals dynamic immunodominance profiles of CD8+ T memory cells in convalescent COVID‐19 donors13
Impact of adaptive natural killer cells, KLRC2 genotype and cytomegalovirus reactivation on late mortality in patients with severe COVID‐19 lung disease13
High expression of CD38 and MHC class II on CD8+ T cells during severe influenza disease reflects bystander activation and trogocytosis13
Validation and performance of a multiplex serology assay to quantify antibody responses following SARS‐CoV‐2 infection or vaccination13
Adoptive T‐cell therapy targeting Epstein–Barr virus as a treatment for multiple sclerosis12
Glycolipid‐peptide conjugate vaccines elicit CD8+ T‐cell responses and prevent breast cancer metastasis12
High‐resolution analysis of individual spike peptide‐specific CD4+ T‐cell responses in vaccine recipients and COVID‐19 patients12
YTHDF2 promotes temozolomide resistance in glioblastoma by activation of the Akt and NF‐κB signalling pathways via inhibiting EPHB3 and TNFAIP312
Designing the next‐generation therapeutic vaccines to cure chronic hepatitis B: focus on antigen presentation, vaccine properties and effect measures11
Interleukin‐1 pathway in active large vessel vasculitis patients with a poor prognosis: a longitudinal transcriptome analysis11
Rapid whole‐blood assay to detect SARS‐CoV‐2‐specific memory T‐cell immunity following a single dose of AstraZeneca ChAdOx1‐S COVID‐19 vaccine11
Effect of washed versus unwashed red blood cells on transfusion‐related immune responses in preterm newborns10
TGF‐β‐activated kinase‐1 inhibitor LL‐Z1640‐2 reduces joint inflammation and bone destruction in mouse models of rheumatoid arthritis by inhibiting NLRP3 inflammasome, TACE, TNF‐α and RANKL expression10
No evidence that plasmablasts transdifferentiate into developing neutrophils in severe COVID‐19 disease10
A lymphodepleted non‐human primate model for the assessment of acute on‐target and off‐tumor toxicity of human chimeric antigen receptor‐T cells10
LIR‐1 educates expanded human NK cells and defines a unique antitumor NK cell subset with potent antibody‐dependent cellular cytotoxicity10
Hypothesis: Febrile infection‐related epilepsy syndrome is a microglial NLRP3 inflammasome/IL‐1 axis‐driven autoinflammatory syndrome10
Diabetes induced by checkpoint inhibition in nonobese diabetic mice can be prevented or reversed by a JAK1/JAK2 inhibitor10
An autologous colonic organoid‐derived monolayer model to study immune: bacterial interactions in Crohn's disease patients10
A novel dual NLRP1 and NLRP3 inflammasome inhibitor for the treatment of inflammatory diseases10
Detailed bladder cancer immunoprofiling reveals new clues for immunotherapeutic strategies10
Epstein–Barr virus and multiple sclerosis: moving from questions of association to questions of mechanism9
IL‐33/ST2 axis deficiency exacerbates neutrophil‐dominant allergic airway inflammation9
Novel high‐affinity EGFRvIII‐specific chimeric antigen receptor T cells effectively eliminate human glioblastoma9
Bactericidal fully human single‐chain fragment variable antibodies protect mice against methicillin‐resistant Staphylococcusaureus bacteraemia9
Increased mast cell activation in eosinophilic chronic obstructive pulmonary disease9
Retrospective analysis of the efficacy of adjuvant cytokine‐induced killer cell immunotherapy combined with chemotherapy in colorectal cancer patients after surgery9
Epigenetic regulation of inflammation by microRNAs in post‐infectious bronchiolitis obliterans9
Severe COVID‐19 represents an undiagnosed primary immunodeficiency in a high proportion of infected individuals9
The IL‐27/IL‐27R axis is altered in CD4+ and CD8+ T lymphocytes from multiple sclerosis patients9
Activity of the growth hormone‐releasing hormone antagonist MIA602 and its underlying mechanisms of action in sarcoidosis‐like granuloma8
Epstein–Barr virus infection, B‐cell dysfunction and other risk factors converge in gut‐associated lymphoid tissue to drive the immunopathogenesis of multiple sclerosis: a hypothesis8
IFN‐γ facilitates liver fibrogenesis by CD161+CD4+ T cells through a regenerative IL‐23/IL‐17 axis in chronic hepatitis B virus infection8
Quantitative measurement of IgG to SARS‐CoV‐2 antigens using monoclonal antibody‐based enzyme‐linked immunosorbent assays8
Dysfunctional BTN3A together with deregulated immune checkpoints and type I/II IFN dictate defective interplay between pDCs and γδ T cells in melanoma patients, which impacts clinical outcomes8
SKI‐G‐801, an AXL kinase inhibitor, blocks metastasis through inducing anti‐tumor immune responses and potentiates anti‐PD‐1 therapy in mouse cancer models8
IL‐6 receptor blockade for allograft dysfunction after lung transplantation in a patient with COPA syndrome8
Diversification of circulating and tumor‐infiltrating plasmacytoid DCs towards the P3 (CD80+ PDL1)‐pDC subset negatively correlated with clinical outcomes in melanoma patients8
The contribution of the alternative pathway in complement activation on cell surfaces depends on the strength of classical pathway initiation8
Previous SARS‐CoV‐2 infection or a third dose of vaccine elicited cross‐variant neutralising antibodies in vaccinated solid‐organ transplant recipients8
Serological and cellular inflammatory signatures in end‐stage kidney disease and latent tuberculosis8
Generation of plasma cells and CD27IgD B cells during hantavirus infection is associated with distinct pathological findings8
Extreme prematurity and sepsis strongly influence frequencies and functional characteristics of circulating γδ T and natural killer cells8
Pervasive inflammatory activation in patients with deficiency in very‐long‐chain acyl‐coA dehydrogenase (VLCADD)7
Repeated influenza vaccination provides cumulative protection from distinct H3N2 viruses7
Primary immunodeficiency‐related genes in neonatal intensive care unit patients with various genetic immune abnormalities: a multicentre study in China7
Interleukin‐18, IL‐18 binding protein and IL‐18 receptor expression in asthma: a hypothesis showing IL‐18 promotes epithelial cell differentiation7
Immunoregulatory effects of testosterone supplementation combined with exercise training in men with Inclusion Body Myositis: a double‐blind, placebo‐controlled, cross‐over trial7
The immunological link between neonatal lung and eye disease7
The interaction between Epstein–Barr virus and multiple sclerosis genetic risk loci: insights into disease pathogenesis and therapeutic opportunities7
Targeting SARS‐CoV‐2 infection through CAR‐T‐like bispecific T cell engagers incorporating ACE27
Supranutritional selenium suppresses ROS‐induced generation of RANKL‐expressing osteoclastogenic CD4+ T cells and ameliorates rheumatoid arthritis7
G‐CSF induces CD15+ CD14+ cells from granulocytes early in the physiological environment of pregnancy and the cancer immunosuppressive microenvironment7
Homologous peptides derived from influenza A, B and C viruses induce variable CD8+ T cell responses with cross‐reactive potential7
DOCK8 deficiency diminishes thymic T‐regulatory cell development but not thymic deletion6
From bedside to bench: how existing therapies inform the relationship between Epstein–Barr virus and multiple sclerosis6
Circulating CXCR5+ natural killer cells are expanded in patients with myasthenia gravis6
The average copy number variation (CNVA) of chromosome fragments is a potential surrogate for tumor mutational burden in predicting responses to immunotherapy in non‐small‐cell lung cancer6
Importance of crosstalk between the microbiota and the neuroimmune system for tissue homeostasis6
The myeloid cell type I IFN system promotes antitumor immunity over pro‐tumoral inflammation in cancer T‐cell therapy6
Neutrophils contribute to elevated BAFF levels to modulate adaptive immunity in patients with primary immune thrombocytopenia by CD62P and PSGL1 interaction6
Inflammatory cytokines as mediators of retinal endothelial barrier dysfunction in non‐infectious uveitis6
Localised release of matrix metallopeptidase 8 in fatal cerebral malaria6
Human EGFRvIII chimeric antigen receptor T cells demonstrate favorable safety profile and curative responses in orthotopic glioblastoma6
Identification of polo‐like kinase 1 as a therapeutic target in murine lupus6
Increased amphiregulin expression by CD4+ T cells from individuals with asymptomatic Leishmania donovani infection6
Expression of CD49f defines subsets of human regulatory T cells with divergent transcriptional landscape and function that correlate with ulcerative colitis disease activity6
Hypoxia‐inducible factor‐1α regulates the interleukin‐6 production by B cells in rheumatoid arthritis5
Genome‐wide off‐target analyses of CRISPR/Cas9‐mediated T‐cell receptor engineering in primary human T cells5
JAK1/2 inhibitor ruxolitinib promotes the expansion and suppressive action of polymorphonuclear myeloid‐derived suppressor cells via the JAK/STAT and ROS‐MAPK5
Blood transcriptomics identifies immune signatures indicative of infectious complications in childhood cancer patients with febrile neutropenia5
Dopaminergic regulation of inflammation and immunity in Parkinson's disease: friend or foe?5
Combinatorial liposomal peptide vaccine induces IgA and confers protection against influenza virus and bacterial super‐infection5
Heterologous SARS‐CoV‐2 IgA neutralising antibody responses in convalescent plasma5
Vaccine‐related major cutaneous reaction size correlates with cellular‐mediated immune responses after tularaemia immunisation5
Peripheral autoreactive CD8 T‐cell frequencies are too variable to be a reliable predictor of disease progression of human type 1 diabetes5
Roadmap for understanding mechanisms on how Epstein–Barr virus triggers multiple sclerosis and for translating these discoveries in clinical trials5
The efficacy and safety of the combination of axitinib and pembrolizumab‐activated autologous DC‐CIK cell immunotherapy for patients with advanced renal cell carcinoma: a phase 2 study5
Epigenetic modulation enhances immunotherapy for pancreatic ductal adenocarcinoma5
A novel computer vision‐based assessment of neutrophil chemotaxis in patients with severe infection5
High sensitivity and specificity of a 5‐analyte protein and microRNA biosignature for identification of active tuberculosis5
Cord blood group 2 innate lymphoid cells are associated with lung function at 6 weeks of age5
Native and oxidised lipoproteins negatively regulate the serum amyloid A‐induced NLRP3 inflammasome activation in human macrophages5
Metagenomic profiling reveals dominance of gram‐positive bacteria in the gut microbiome shifts associated with immunoglobulin A vasculitis (Henoch–Schönlein Purpura)4
A peptoid interleukin‐15 receptor antagonist suppresses inflammation and arthritis in mice4
Effect of Intralipid infusion on peripheral blood T cells and plasma cytokines in women undergoing assisted reproduction treatment4
The frequency of Treg subsets distinguishes disease activity in ANCA vasculitis4
The immunopathogenesis of SARS‐CoV‐2 infection in children: diagnostics, treatment and prevention4
Preclinical evaluation of cancer immune therapy using patient‐derived tumor antigen‐specific T cells in a novel xenograft platform4
Sex‐bias in CD8+ T‐cell stemness and exhaustion in cancer4
Categorisation of patients based on immune profiles: a new approach to identifying candidates for response to checkpoint inhibitors4
Probabilistic classification of anti‐SARS‐CoV‐2 antibody responses improves seroprevalence estimates4
Impact of maternal engrafted cytomegalovirus‐specific CD8+ T cells in a patient with severe combined immunodeficiency4
Genetic risk for severe COVID‐19 correlates with lower inflammatory marker levels in a SARS‐CoV‐2‐negative cohort4
Heterologous booster vaccination with CoronaVac following prime vaccination with mRNA vaccine4
Naturally derived cytokine peptides limit virus replication and severe disease during influenza A virus infection4
Circulating CCR6+ILC proportions are lower in multiple sclerosis patients4
Dupilumab provides early and durable improvement of symptoms in patients with chronic rhinosinusitis with nasal polyps4
0.057483911514282